3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
522
Neoplasms
470
Carcinoma, Non-Small-Cell Lung
393
Prostatic Neoplasms
302
Colorectal Neoplasms
296
Lung Neoplasms
259
Neoplasm Metastasis
217
Ovarian Neoplasms
198
Leukemia, Myeloid, Acute
194
Pancreatic Neoplasms
185
Multiple Myeloma
172
Squamous Cell Carcinoma of Head and Neck
133
Recurrence
132
Stomach Neoplasms
129
Brain Neoplasms
126
Melanoma
123
Carcinoma, Hepatocellular
123
Endometrial Neoplasms
120
Glioblastoma
118
Triple Negative Breast Neoplasms
111
Precursor Cell Lymphoblastic Leukemia-Lymphoma
105
Hematologic Neoplasms
99
Head and Neck Neoplasms
97
Carcinoma, Renal Cell
96
Lymphoma
93
Urinary Bladder Neoplasms
90
Sarcoma
90
Glioma
88
Lymphoma, Large B-Cell, Diffuse
81
Small Cell Lung Carcinoma
80
Interventions
Letrozole
2
ribociclib
1
palbociclib
1
abemaciclib
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
HR+/HER2- Breast Cancer
×
90 days
×
Clear all
NCT07492641
2026-06-03
KANDELA-302
BeOne Medicines
Phase 3
Recruiting
1,056 enrolled
NCT06998407
2026-05-04
AVZO-023-1001
Avenzo Therapeutics, Inc.
Phase 1/2
Recruiting
380 enrolled